Peripheral arterial disease and isolated systolic hypertension: The ATTEST Study

Journal of Human Hypertension

Volumn 23, Issue 3, 2009, Pages 182-187

  Safar, M E ^a   Priollet, P ^b   Luizy, F ^a   Mourad, J J ^c   Cacoub, P ^d   Levesque, H ^e   Benelbaz, J ^f   Michon, P ^g   Herrmann, M A ^h   Blacher, J ^a  

^a HÔTEL DIEU   (France)

^b SAINT JOSEPH HOSPITAL   (France)

^c AVICENNE HOSPITAL   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e ROUEN UNIVERSITY HOSPITAL   (France)

^f Sanofi Aventis ^*  (France)

^g SANOFI   (France)

^h BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; TICLOPIDINE; VASOACTIVE AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DYSLIPIDEMIA; FEMALE; GENERAL PRACTITIONER; HUMAN; HYPERTENSION; ISOLATED SYSTOLIC HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; POPULATION RESEARCH; PREVALENCE; PRIMARY MEDICAL CARE; SYSTOLIC BLOOD PRESSURE; SYSTOLIC DIASTOLIC HYPERTENSION; SYSTOLIC HYPERTENSION;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CEREBROVASCULAR DISORDERS; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; FAMILY PRACTICE; FRANCE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PREVALENCE; PRIMARY HEALTH CARE; SECONDARY PREVENTION;

EID: 60549117497     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2008.121     Document Type: Article

References (26)

1. Lawes CM, Vander Hoorn S, Rodgers A. International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371: 1513-1518.
2. Arterial stiffness in hypertension. In: Safar ME and O'Rourke ME (eds). Handbook of Hypertensio, vol. 23. Elsevier: Edinburgh, UK, 2006, pp 3-62, 75-136, 459-501.
3. Verdecchia P, Reboldi G, Angeli F, Gattobigio R, Bentivoglio M, Thijs L et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005; 46: 386-392.
4. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.
5. Blacher J, Cacoub P, Luizy F, Mourad JJ, Levesque H, Benelbaz J et al Peripheral arterial disease versus other localizations of vascular disease: The ATTEST study. J Vasc Surg 2006; 44: 314-318.
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
7. Safar ME, Smulyan H. Systolic versus diastolic blood pressure, 2000. In: Bulpitt CJ (ed). Handbook of Hypertension. Elsevier Science BV: Amsterdam, pp 73-85.
8. Spence JD, Sibbald WJ, Cape RD. Pseudohypertension in the ederly. Clin Sci Molec Med 1978; 55: 399s-402s.
9. Messerli FH, Ventura HO, Amodeo C. Osler's maneuver and pseudohypertension. New Engl J Med 1985; 312: 1348-1351.
10. Safar ME, Simon AC. Hemodynamics in systolic hypertension, 1986. In: Zanchetti A, Tarazi RC (eds). Handbook of Hypertension, vol 7: Physiopathology of Hypertension, Cardiovascular Aspects. Elsevier Science: Amsterdam, pp 70-84.
11. Safar ME, Laurent ST, Asmar RE, Safavian A, London GM. Systolic hypertension in patients with arteriosclerosis obliterans of the lower limbs. Angiology 1987; 28: 287-295.
12. Levenson JA, Simon AC, Fiessinger JN, Safar ME, London GM, Housset EM. Systemic arterial compliance in patients with arteriosclerosis obliterans of the lower limbs; Observation of the effect of intravenous propranolol. Arteriosclerosis 1982; 2: 266-271.
13. Levenson JA, Simon ACH, Safar ME, Fiessinger JN, Housset EM. Systolic hypertension in patients with arteriosclerosis of the lower limbs. Clin Exper Hyper Theory Practice 1982; A4(7): 1059-1072.
14. Van Popele NM, Grobbee DE, Bots ML, Asmar R, Topouchian J, Reneman RS et al. Association between arterial stiffness and atherosclerosis. The Rotterdam Study. Stroke 2001; 32: 454-460.
15. Labouret G, Achimastos A, Benetos A, Safar M, Housset E. L'hypertension arte'rielle des ampute's traumatiques. Press Med 1983; 21: 1349-1354.
16. Levenson JA, Simon AC, Maarek BE, Gitelman RJ, Fiessinger JN, Safar ME. Regional compliance of brachial artery and saline infusion in patients with arteriosclerosis obliterans. Arteriosclerosis 1985; 5: 80-87.
17. Achimastos A, Brahimi M, Raison J, Billaud E, Ayache M, Moatti N et al. Plasma insulin, plasminogen activator inhibitor, and ankle-brachial systolic blood pressure ratio in overweight hypertensive subjects. J Hum Hypertens 1999; 13: 329-335.
18. Simon AC, Levenson JA, Levy BI, Bouthier JE, Peronneau PP, Safar ME. Effects of nitroglycerine on peripheral large arteries in hypertension. Br J Clin Pharmacol 1982; 14: 241-245.
19. Louie J, Isaacson JA, Zierler RE, Bergelin RO, Strandness DE. Prevalence of carotid and lower extremity arterial disease in patients with renal artery stenosis. Am J Hypertens 1994; 7: 436-439.
20. Brewer LC, Chai HS, Bailey KR, Kullo IJ. Measures of arterial stiffness and wave reflection are associated with walking distance in patients with peripheral arterial disease. Atherosclerosis 2007; 191: 384-390.
21. Safar ME, Totomoukouo JJ, Asmar RA, Laurent ST. Increased pulse pressure in patients with arteriosclerosis obliterans of the lower limb. Arteriosclerosis 1987; 7: 232-237.
22. Farrar DJ J, Malindzak GS, Johnson G. Large Vessel Impedance in Peripheral Atherosclerosis. Circulation 1977; 56(3 Suppl II): 171-178.
23. Yusuf S, Sleight P, Pogue J, Boch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
24. Achimastos AA, Natoli AK, Lawler A, Blombery PA, Kingwell BA. Ramipril reduces large-artery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture. Hypertension 2005; 45: 1194-1199.
25. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357: 995-1001.
26. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317-1324.